4 active not recruiting, 3 completed, 1 recruiting, 1 suspended. 3 Phase 2, 2 Early Phase 1, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Suspended 1 |
| Early Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Pathologic Stage IIIA Gastric Cancer AJCC v8: new trials by email Literature Review of Pathologic Stage IIIA Gastric Cancer AJCC v8 trials Research Report on Pathologic Stage IIIA Gastric Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers Capecitabine, Docetaxel, Fluorouracil - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2025-12-31 | 2025-02-07 | |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Lenvatinib, Pembrolizumab - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2022-02-14 | 2026-07-16 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Paclitaxel, Quality-of-Life Assessment, Ramucirumab - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | Academic and Community Cancer Research United | 116 | 2021-06-16 | 2024-04-01 |
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE - Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma | Phase 2 | Suspended | Thomas Jefferson University | 48 | 2020-11-10 | 2026-09-14 |
| Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma Capecitabine, Fluorouracil, Radiation Therapy - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2020-08-11 | 2026-07-16 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study Patient Monitoring System, Questionnaire Administration, Consultation - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Completed | Thomas Jefferson University | 34 | 2020-04-15 | 2025-05-15 |
| Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery Best Practice, Quality-of-Life Assessment, Questionnaire Administration - Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Gastric Cancer AJCC v8 | Active not recruiting | City of Hope Medical Center | 52 | 2019-01-08 | 2026-10-22 | |
| Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Fluorouracil, Intensity-Modulated Radiation Therapy, Ipilimumab - Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2019-01-07 | 2026-10-06 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma Pembrolizumab - Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 9 | 2018-02-09 | 2023-11-18 |
Colorectal Neoplasms (3) · Gastrointestinal Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urogenital Neoplasms (1) · Uterine Cervical Neoplasms (1)
Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms by Site (3) · Rectal Diseases (3) · Neoplasms (2) · Pancreatic Diseases (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma (1)
Fluorouracil (3) · dehydroftorafur (3) · Capecitabine (2) · Oxaliplatin (2) · Radiation (2) · Radiotherapy (2) · pembrolizumab (2) · CTLA-4 Antigen (1) · Docetaxel (1) · Ipilimumab (1) · Leucovorin (1) · Nivolumab (1) · Paclitaxel (1) · Practice Guidelines as Topic (1) · Radiotherapy, Intensity-Modulated (1)
M.D. Anderson Cancer Center (4) · City of Hope Medical Center (2) · Thomas Jefferson University (2) · Academic and Community Cancer Research United (1) · Ohio State University Comprehensive Cancer Center (1)
United States (9)
Mariela Blum (2) · Babar Bashir, MD (1) · Brian D Badgwell (1) · Dayssy A Diaz Pardo, MD, MS (1) · Jaffer A Ajani (1) · Kuang-Yi Wen, MD (1) · Laleh Melstrom (1) · Mohamad B Sonbol (1) · Yanghee Woo (1)
P30CA015083 (1), P30CA033572 (1)